Olo Inc
Change company Symbol lookup
Select an option...
OLO Olo Inc
FTII Futuretech II Acquisition Corp
CTLP Cantaloupe Inc
ACQRU Independence Holdings Corp
ARHS Arhaus Inc
PARA Paramount Global
TD Toronto-Dominion Bank
GL Globe Life Inc
PRI Primerica Inc
AMH American Homes 4 Rent
Go

Information Technology : Software | Small Cap Growth
Company profile

Olo Inc. is an open software as a service (SaaS) platform for restaurants. Its platform powers restaurant brands’ on-demand digital commerce operations, enabling digital ordering, delivery, front-of-house management, and payments, while enhancing the restaurants’ direct consumer relationships. The Company provides restaurants with a business-to-business-to-consumer, enterprise-grade, open SaaS platform to manage their digital businesses and enable fast and more personalized experiences for their customers. Its platform and application programming interfaces, that integrate with a range of solutions, unifying technologies across the restaurant ecosystem. Its open SaaS platform includes various core modules: order management, delivery enablement, customer engagement, front-of-house, and payment. Its order management offers a suite of fully integrated, white-label, on-demand digital commerce and channel management solutions, enabling guests to order and pay directly from restaurants.

Postmarket

Last Trade
Delayed
$0.00
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$8.02
Day's Change
0.25 (3.22%)
Bid
--
Ask
--
B/A Size
--
Day's High
8.14
Day's Low
7.83
Volume
(Average)
Volume:
991,079

10-day average volume:
1,011,298
991,079

22nd Century Group (Nasdaq: XXII) GVB Biopharma to Exhibit at MJBizCon in Las Vegas

9:25 am ET November 15, 2022 (Globe Newswire) Print
22nd Century Group (Nasdaq: XXII) GVB Biopharma to Exhibit at MJBizCon in Las VegasGlobeNewswireNovember 15, 2022

BUFFALO, N.Y., Nov. 15, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, today announced that the Company's GVB Biopharma business will attend and be an exhibitor at MJBizCon in Las Vegas on November 16 to 18, 2022.

"We're excited to be exhibiting at MJBizCon for the fourth year, and this time with the combined GVB and 22nd Century team, including Hugh Kinsman, Steven Przybyla, Calvin Treat, John Miller, and the GVB executive team," said James A. Mish, chief executive officer of 22nd Century Group. "MJBizCon is an excellent opportunity to showcase our technical expertise and capabilities, from receptor science and transformative plant genetics to finished ingredients and CDMO-formulated products for the global consumer products and pharmaceutical industry."

Find GVB Biopharma at MJBizCon, November 16 to 18, 2022, at booth #9945.

About GVB Biopharma

GVB Biopharma, a 22nd Century company, is a global-scale specialty ingredient supplier and contract development & manufacturing organization (CDMO) with manufacturing locations in Nevada and Oregon. GVB is the largest merchant provider of cannabinoid extracts and isolates in North America with a focus on cannabidiol (CBD) and cannabigerol (CBG) extracted and refined at an industrial scale into distillates and isolates. GVB Biopharma's facilities are NSF International audited and are cGMP Registered for dietary supplements manufacturing. GVB is widely regarded as a best-in-class operator with a leading position in the hemp-derived active ingredients market, with around 15% market share and growing. GVB is also a white-label contract manufacturer of tinctures, gel capsules, gummies, mints, tablets, topical, and vape offerings.

About 22nd Century Group, Inc.

22nd Century Group, Inc. (Nasdaq: XXII) is a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the FDA's Comprehensive Plan to address the widespread death and disease caused by smoking. The Company received the first and only FDA MRTP authorization of a combustible cigarette in December 2021. In tobacco, hemp/cannabis, and hop plants, 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.

Learn more at xxiicentury.com, on Twitter, on LinkedIn, and on YouTube.

Learn more about VLN(R) at tryvln.com.

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "explore," "foresee," "goal," "guidance," "intend," "likely," "may," "plan," "potential," "predict," "preliminary," "probable," "project," "promising," "seek," "should," "will," "would," and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in "Risk Factors" in the Company's Annual Report on Form 10-K filed on March 1, 2022, and in the Company's Quarterly Report filed on August 9, 2022. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact

Mei Kuo

22nd Century Group, Inc.

Director, Communications & Investor Relations

mkuo@xxiicentury.com

Darrow Associates Investor Relations

Matt Kreps

T: 214-597-8200

mkreps@darrowir.com



Primary Logo

comtex tracking

COMTEX_418929898/2010/2022-11-15T09:25:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.